[
    [
        {
            "time": "",
            "original_text": "沃森生物：公司疫苗产品的有效期一般为2年，不存在去年批签发的疫苗跨年作废的问题",
            "features": {
                "keywords": [
                    "沃森生物",
                    "疫苗",
                    "有效期",
                    "批签发",
                    "作废"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "沃森生物：公司疫苗产品的有效期一般为2年，不存在去年批签发的疫苗跨年作废的问题",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "一年净赚33亿却难有话语权，HPV疫苗或纳入免疫规划，智飞生物难阻毛利率、增速双双下滑 盈利能力下降",
            "features": {
                "keywords": [
                    "智飞生物",
                    "HPV疫苗",
                    "免疫规划",
                    "毛利率",
                    "增速",
                    "盈利能力"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "一年净赚33亿却难有话语权，HPV疫苗或纳入免疫规划，智飞生物难阻毛利率、增速双双下滑 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]